LEN vs PLRX · rev $34.19B vs $77.3M cap
LEN (LEN) versus Pliant Therapeutics Inc (PLRX) — a side-by-side from cached financials, not a winner call.
LEN (LEN) common stock.
Pliant Therapeutics Inc (PLRX) is a biotechnology company listed on US.
Latest reported LEN revenue for 2025-11-30 was $34.19B. Net income was $2.08B. Revenue was down 3.5% from 2024-11-30 to 2025-11-30. LEN currently screens at market cap $0.
Latest reported PLRX revenue for 2024-12-31 was $0. Net income was -$210.3M. Revenue was down 100.0% from 2023-12-31 to 2024-12-31. PLRX currently screens at market cap $77.3M.
LEN currently screens at market cap $0. PLRX currently screens at market cap $77.3M.
Not investment advice. Open the LEN and PLRX stock pages for the full models.
Not investment advice.